NCI Director Monica Bertagnolli delivers her first public speech at the ECOG-ACRIN Cancer Research Group meeting
Leaders and members of the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) were honored to be the recipients of the first public ...
Tag: ECOGACRIN
ECOG-ACRIN completes the first randomized phase 3 clinical trial of neoadjuvant immunotherapy in patients with kidney cancer
Philadelphia, September 8 – The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase ...
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211)
Background:Patients with advanced pancreatic neuroendocrine tumors (NETs) have few treatment options that yield objective tumor response. Retrospective and small, prospective ...
ECOG-ACRIN research highlights at ASCO 2022
Philadelphia, May 27, 2022—Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present a wide range of study results at ...
ECOG-ACRIN opens a new NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations
The groundbreaking NCI-MATCH trial continues to offer treatment opportunities for adult patients with relapsed, refractory cancers. A new treatment arm ...